CA2428971A1 - Conjugues d'un agent therapeutique et d'un porteur peptidique - Google Patents

Conjugues d'un agent therapeutique et d'un porteur peptidique Download PDF

Info

Publication number
CA2428971A1
CA2428971A1 CA002428971A CA2428971A CA2428971A1 CA 2428971 A1 CA2428971 A1 CA 2428971A1 CA 002428971 A CA002428971 A CA 002428971A CA 2428971 A CA2428971 A CA 2428971A CA 2428971 A1 CA2428971 A1 CA 2428971A1
Authority
CA
Canada
Prior art keywords
polypeptide
composition
active agent
peptide
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002428971A
Other languages
English (en)
Inventor
Thomas Piccariello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/US2001/043089 external-priority patent/WO2003034980A2/fr
Publication of CA2428971A1 publication Critical patent/CA2428971A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne une composition comprenant un polypeptide et du benzatropine mésylate relié par covalence au polypeptide. La présente invention concerne également un procédé d'administration de benzatropine mésylate à un patient, consistant à administrer au patient une composition comprenant un polypeptide et du benzatropine mésylate relié par covalence au polypeptide. En outre, cette invention concerne un procédé permettant de protéger le benzatropine mésylate contre la dégradation, qui consiste à relier le benzatropine mésylate par covalence à un polypeptide. L'invention concerne également un procédé de régulation de la libération de benzatropine mésylate d'une composition, consistant à relier par covalence le benzatropine mésylate au polypeptide.
CA002428971A 2000-11-14 2001-11-14 Conjugues d'un agent therapeutique et d'un porteur peptidique Abandoned CA2428971A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27462200P 2000-11-14 2000-11-14
US60/274,622 2000-11-14
PCT/US2001/043089 WO2003034980A2 (fr) 2000-11-14 2001-11-14 Nouveau compose pharmaceutique contenant du sulfate d'abacavir et procedes de fabrication et d'utilisation associes

Publications (1)

Publication Number Publication Date
CA2428971A1 true CA2428971A1 (fr) 2003-05-01

Family

ID=23048971

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002428971A Abandoned CA2428971A1 (fr) 2000-11-14 2001-11-14 Conjugues d'un agent therapeutique et d'un porteur peptidique

Country Status (2)

Country Link
JP (2) JP2006516948A (fr)
CA (1) CA2428971A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI432204B (zh) * 2011-06-03 2014-04-01 Taiwan Hopax Chems Mfg Co Ltd 對抗自由基的醫藥組合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356166A (en) * 1978-12-08 1982-10-26 University Of Utah Time-release chemical delivery system
US5534496A (en) * 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
NZ291368A (en) * 1994-08-19 1999-04-29 Wallone Region A compound comprising a marker or a therapeutic agent linked to a ligand containing amino acids wherein the marker or agent is cleaved from the ligand to permit entry into the cell of the marker or agent, medicaments for treating tumours; diagnostic devices
US5846743A (en) * 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
WO1996040123A1 (fr) * 1995-06-07 1996-12-19 Swadesh Joel K Conjugues cibles sur des cellules de traitement de l'antigene
US5846473A (en) * 1996-01-08 1998-12-08 Gb Electrical, Inc. Removal of injection-molded tie from mold by temporarily retaining core between pawl and abutment surface of tie
ES2448467T3 (es) * 1996-03-12 2014-03-14 Pg-Txl Company, L.P. Profármacos solubles en agua
AU729643B2 (en) * 1996-05-01 2001-02-08 Antivirals Inc. Polypeptide conjugates for transporting substances across cell membranes
DK0971713T3 (da) * 1997-03-03 2003-09-22 Eisai Co Ltd Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
PT1144011E (pt) * 1998-12-11 2010-06-16 Coulter Pharm Inc Compostos pró-fármacos e processo para a sua preparação
US6673367B1 (en) * 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
ES2255490T3 (es) * 1999-03-31 2006-07-01 Janssen Pharmaceutica N.V. Almidon pregelatinizado en una formulacion de liberacion controlada.
AU769799B2 (en) * 1999-05-13 2004-02-05 Comar, Llc Locking helical closure system

Also Published As

Publication number Publication date
JP2010189419A (ja) 2010-09-02
JP2006516948A (ja) 2006-07-13

Similar Documents

Publication Publication Date Title
US6716452B1 (en) Active agent delivery systems and methods for protecting and administering active agents
JP4878732B2 (ja) 規制物質の濫用を防ぐための新規な持続放出製薬化合物
AU2002306500B2 (en) Transporters comprising spaced arginine moieties
US20020099013A1 (en) Active agent delivery systems and methods for protecting and administering active agents
WO2003101476A1 (fr) Systeme d'administration de substances actives et methodes de protection et d'administration de substances actives
AU2001286599A1 (en) Active agent delivery systems and methods for protecting and administering active agents
AU2003217676A1 (en) Active agent delivery systems and methods for protecting and administering active agents
EP2091914A1 (fr) Systèmes de libération transdermique de peptides et composés associés
US8080519B2 (en) Compositions and methods for enhanced pharmacological activity of compositions comprising peptide drug substances
WO2002051432A1 (fr) Nouveau compose pharmaceutique, ses procedes de preparation, et son utilisation
CA2428971A1 (fr) Conjugues d'un agent therapeutique et d'un porteur peptidique
EP1357928B1 (fr) Nouveau composé pharmaceutique et procédés de fabrication et d'utilisation de ce composé
EP1401374B1 (fr) Nouveau compose pharmaceutique contenant d'atenolol et procedes de fabrication et d'utilisation associes
JP6851977B2 (ja) マクロライド系免疫抑制剤の高分子誘導体
US8772248B2 (en) Drug delivery system
CA2434831C (fr) Drogues a base de polypeptide
JP2004523480A (ja) 活性作用物質送達系ならびに活性作用物質の保護および投与方法
AU2001298033B2 (en) A novel pharmaceutical compound containing abacavir sulfate and methods of making and using same
KR100905628B1 (ko) 활성제 전달 시스템 및 활성제의 보호 및 투여 방법
EP2080511A2 (fr) Systèmes d'administration de principe actif et procédé pour la protection et l'administration de principes actifs
CN101460496A (zh) 单和二取代的羟考酮化合物和组合物
AU5672094A (en) Permeability enhancers for ionic therapeutic polymers
WO1994012516A9 (fr) Composes favorisant la permeabilite des membranes aux polymeres therapeutiques ioniques
AU2007203485A1 (en) A novel pharmaceutical compound containing Abacavir sulfate and methods of making and using same
WO1994018230A1 (fr) Inhibition de la replication du vih a l'aide de complexes peptide-cuivre

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130827